Together, these results suggested that MET, EGFR, HER2, and HER3 activate AKT and ERK signalling pathways and promote cell proliferation and survival in lung cancer cells with MET amplification, whereas MET, HER2, and RET activate the STAT3 signalling pathway and promote cell migration. This evidence concerns the gene AKT1 and lung carcinoma.